TICKERNERD
Menu
STAASTAAHealthcare · Medical Instruments & Supplies

STAA Stock Forecast: STAAR Surgical Co. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$23
+1.81% on the day

The 12 Wall Street analysts covering STAAR Surgical Co. hold a median 12-month price target of $28 — +19.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 14 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.1B
Ticker Nerd rank
73 / 100
Median analyst target
$28
Analysts covering
12
Revenue$93.5M+111.0% y/y
Operating income$10.1M
Net income$8.1M
Free cash flow$19.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
−11.9%
YTD
−0.1%
1Y
−16.7%
From 52W high
−30.8%
From 52W low
+43.3%
$16
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STAA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores STAAR Surgical Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
82
Issuance
72
Quality
62
Volatility
61
Momentum
56
Size
43
Revisions
42
Accruals
37

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STAA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STAA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26STAAHigh $37Median $28Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
3 Buy8 Hold1 Sell
Low $19Median $28High $37

The green dot is the last close — the median target sits +19.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Aug 2026StifelMaintainsHold$31 → $28
13 Aug 2026UBSMaintainsSell$20 → $19
13 Aug 2026WedbushMaintainsOutperform$40 → $37
4 Aug 2026WedbushReiteratesOutperform$40
4 Aug 2026WedbushReiteratesOutperform—
28 July 2026UBSInitiatesSell—
28 July 2026UBSInitiatesSell$20
22 July 2026WedbushReiteratesOutperform—
22 July 2026WedbushReiteratesOutperform$40
16 July 2026WedbushReiteratesOutperform—
16 July 2026WedbushReiteratesOutperform$40
29 May 2026WedbushReiteratesOutperform—
15 May 2026Wells FargoMaintainsEqual-Weight—
14 May 2026Canaccord GenuityMaintainsBuy—
14 May 2026MizuhoMaintainsNeutral—
14 May 2026Piper SandlerMaintainsNeutral—
14 May 2026StifelMaintainsHold—
14 May 2026WedbushUpgradeOutperform—
9 Apr 2026Canaccord GenuityUpgradeBuy—
9 Apr 2026WedbushMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STAA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STAA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, STAAR Surgical Co. returned −16.7% against +17.0% for the S&P 500, dividends included.

STAA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26STAAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STAA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.6%
Analysts raising
3
Analysts cutting
4
Fundamentals

STAAR Surgical Co. (STAA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
283.3×

Cheaper than 2% of US stocks

Price / sales
3.3×

Cheaper than 38% of US stocks

Price / book
3.1×

Cheaper than 32% of US stocks

EV / EBITDA
19.9×

Cheaper than 15% of US stocks

Growth & margins
Revenue growth (YoY)
111.0%

Higher than 93% of US stocks

Earnings growth (YoY)
111.0%

Higher than 85% of US stocks

Gross margin
74.5%

Higher than 87% of US stocks

Operating margin
10.9%

Higher than 66% of US stocks

Net margin
1.1%

Higher than 50% of US stocks

Returns & dividend
Return on equity
1.1%

Higher than 45% of US stocks

Return on assets
5.6%

Higher than 80% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

STAAR Surgical Co. (STAA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • STAAR Surgical Co. has a market value of $1.1B and an enterprise value of $990.7M.

  • Revenue in the twelve months to 30 June 2026: $339.6M. The latest quarter grew 111.0% year on year.

  • Net income over the same four quarters: $3.8M, a 1.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.07.

  • Free cash flow in the twelve months to 30 June 2026: −$6.7M.

  • STAAR Surgical Co. spent $6.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 50.1M.

  • Trailing P/E: 283.3×; forward P/E: 22.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • STAAR Surgical Co. employs 921 people — $369K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

STAA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
STAASTAAR Surgical Co.$1.1B
73
KMTSKestra Medical Technologies Ltd.$1.4B
22
AZTAAzenta, Inc.$1.5B
81
NNNNAnbio Biotechnology$879.2M
17
BLFSBioLife Solutions, Inc.$1.7B
91
LMATLeMaitre Vascular, Inc.$1.8B
69
XRAYDentsply Sirona, Inc.$2.1B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own STAAR Surgical Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STAA news & analysis

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

Business Wire · 10 Sept 2026positive

STAAR Surgical released a new report titled "The Future of Refractive Surgery," described as the first comprehensive global market analysis showing a consistent, multi-market shift toward implantable lens correction, driven by durable tailwinds on both the demand and clinical sides of the market.

Why it matters — The report highlights a structural migration toward lens-based vision correction, a market segment where STAAR's EVO ICL family is a leading product, reinforcing the company's position in the phakic IOL market.

STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

Business Wire · 8 Sept 2026positive

STAAR Surgical announced the appointment of David Bailey, a former CEO of the company, as Chief Commercial Officer. Bailey will join STAAR's executive committee and report to President and CEO Warren Foust.

Why it matters — Bailey's deep familiarity with STAAR as a former CEO could bring commercial leadership experience to the company's executive team.

Deciphering Staar Surgical (STAA) International Revenue Trends

Zacks Investment Research · 17 Aug 2026neutral

Zacks Investment Research published a review of STAAR Surgical's (STAA) international revenue performance and how those trends influence Wall Street analysts' forecasts and the stock's future prospects.

Why it matters — A STAA watcher would care because international revenue trends are central to analysts' predictions about the company's future performance and stock outlook.

STAAR Surgical Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

STAAR Surgical reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier. CEO Warren Foust attributed the growth to contributions from China, the Americas and parts of Europe, and called it the company's strongest first half of revenue performance.

Why it matters — The report highlights strong revenue growth across key markets, indicating robust demand for STAAR Surgical's products during the period.

FAQ

Frequently asked questions about STAA stock

What is the STAA stock price forecast for 2026-2027?

The 12 Wall Street analysts covering STAAR Surgical Co. have a median 12-month price target of $28, with estimates ranging from $19 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STAA stock a buy right now?

Of the 12 analysts covering STAAR Surgical Co., 3 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks STAAR Surgical Co. 73 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STAA?

As at 14 Sept 2026, STAAR Surgical Co. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will STAA stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +19.2% from the last close, and Ticker Nerd's factor model ranks STAAR Surgical Co. 73 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STAA stock forecast for 2030?

No analyst covering STAAR Surgical Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STAA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $37 over the next 12 months.

How has STAA stock performed over the past year?

STAAR Surgical Co. returned -16.7% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does STAAR Surgical Co. do?

STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.

What is the latest news on STAA?

The most recent item we track (Business Wire, 10 Sept 2026): "STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction". STAAR Surgical released a new report titled "The Future of Refractive Surgery," described as the first comprehensive global market analysis showing a consistent, multi-market shift toward implantable lens correction, driven by durable tailwinds on both the demand and clinical sides of the market.

Company

About STAAR Surgical Co.

STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company focuses on ophthalmic surgery solutions that are used by eye care professionals seeking lens-based vision correction options. STAAR Surgical also offers accessory systems that support lens implantation procedures and help deliver its products into the eye. Headquartered in Lake Forest, California, and founded in 1982, STAAR Surgical serves a global market centered on eye care and vision correction, with a business model built around specialized surgical devices and related procedure support.

CEO Mr. Warren Foust · 921 employees · United States · https://www.staar.com